Stryker Stock - Analyst consensus stays constructive

Stryker stock continues to benefit from a broadly constructive analyst view, with a solid “Moderate Buy” consensus and double-digit upside potential implied by average price targets. A look at the current ratings landscape and how it frames the shares.

Edited by ad hoc news Operations & Strategy Desk. Verified prior to publication on 06/17/2026, 17:13 CET. Details in the imprint.

Stryker Corp. (US8636671013) sits on a broadly constructive analyst backdrop, with most houses still rating the stock at Buy or equivalent according to current consensus data. The distribution of recommendations and price targets gives investors a structured view of how Wall Street frames the medtech group.

How analysts rate Stryker

According to current consensus data compiled by MarketBeat, Stryker carries an average rating of “Moderate Buy”, based on roughly two dozen active recommendations. The sample includes a clear majority of Buy or Outperform ratings, alongside a smaller group of Hold calls.

On this view, Stryker remains a high-quality medtech name where analysts expect mid- to high-single-digit organic growth and continued margin resilience. Some houses have trimmed targets recently, but the core positive thesis around procedure growth and product breadth largely remains intact.

What the targets imply

The same data set shows an average 12-month price target of around $395 per share, implying a double-digit percentage upside from recent trading levels. The dispersion of targets is moderate, with most clustered in a relatively narrow corridor around the mean.

Net-net, this points to a market view that Stryker is not a deep value play but a structural grower, where investors pay a premium multiple for earnings visibility. For many brokers, that premium is justified by Stryker’s diversified portfolio, recurring revenue exposure and disciplined capital allocation.

The operations behind the stock

Stryker’s operating profile is built on three large pillars: Orthopaedics, MedSurg and Neurotechnology and Spine, which together generated more than $20 billion in annual sales in the most recent fiscal year, according to the company’s reporting. Each pillar targets specific procedure categories and hospital budgets.

Management’s strategy emphasizes sustained R&D spending, targeted M&A and geographic expansion, particularly in higher-growth markets. Against this backdrop, analysts often highlight Stryker’s ability to integrate acquisitions and maintain innovation cycles across its portfolio.

How the company makes money

Stryker generates revenue mainly by selling surgical implants, instruments, medical devices and related services to hospitals and clinics worldwide. The mix includes capital equipment, such as surgical robots, and disposable products that create ongoing, procedure-linked revenue streams.

Where the stock trades today

The shares of Stryker Corp. (US8636671013) trade on the New York Stock Exchange at $310.58 as of 06/17/2026, 17:13 CET.

Key facts on Stryker stock

• Company: Stryker Corp.
• ISIN: US8636671013
• WKN: 864952
• Ticker: SYK
• Venue: NYSE
• Price (as of 06/17/2026, 17:13 CET): 310.58 USD
• Market cap: 118,000,000,000 USD (as of 06/17/2026)
• Sector / Industry: Health Care - Medical Equipment
• Index membership: S&P 500
• Next earnings date: 07/25/2026

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.